Cargando…

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Rui-Ru, Qu, Yajin, Zhu, Hua, Yang, Yumei, Vogel, Annette B., Sahin, Ugur, Qin, Chuan, Hui, Aimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066210/ https://www.ncbi.nlm.nih.gov/pubmed/33915773 http://dx.doi.org/10.3390/vaccines9040324

Ejemplares similares

Comparative pathology of the nasal epithelium in K18-hACE2 Tg mice, hACE2 Tg mice, and hamsters infected with SARS-CoV-2
por: Yu, Pin, et al.
Publicado: (2022)

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice
por: Muturi, Elishiba, et al.
Publicado: (2022)

Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice
por: DeDiego, Marta L., et al.
Publicado: (2008)

The Tissue Distribution of SARS-CoV-2 in Transgenic Mice With Inducible Ubiquitous Expression of hACE2
por: Dolskiy, Alexander A., et al.
Publicado: (2022)

Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice
por: Vidal, Enric, et al.
Publicado: (2021)

SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function
por: Winkler, Emma S., et al.
Publicado: (2020)

Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice
por: Bar-On, Liat, et al.
Publicado: (2022)

Highly susceptible SARS-CoV-2 model in CAG promoter–driven hACE2-transgenic mice
por: Asaka, Masamitsu N., et al.
Publicado: (2021)

An inducible hACE2 transgenic mouse model recapitulates SARS-CoV-2 infection and pathogenesis in vivo
por: Liu, Kuo, et al.
Publicado: (2023)

Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression
por: Carossino, Mariano, et al.
Publicado: (2022)

Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors
por: Cugno, Massimo, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research
por: Dedoni, Simona, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice
por: Rizvi, Zaigham Abbas, et al.
Publicado: (2023)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
por: Valentini, Diletta, et al.
Publicado: (2022)

Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice
por: Shang, Chao, et al.
Publicado: (2021)

In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice
por: Amruta, Narayanappa, et al.
Publicado: (2021)

Effect of severe acute respiratory syndrome coronavirus 2 infection during pregnancy in K18-hACE2 transgenic mice
por: Kim, Byeongseok, et al.
Publicado: (2023)

Therapeutic Effect of C-Vx Substance in K18-hACE2 Transgenic Mice Infected with SARS-CoV-2
por: Ulbegi Polat, Hivda, et al.
Publicado: (2023)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice
por: Jiang, Xiaoliang, et al.
Publicado: (2022)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Zou, Jing, et al.
Publicado: (2021)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
por: Papadokostaki, Eleni, et al.
Publicado: (2022)

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
por: Dimeglio, Chloé, et al.
Publicado: (2023)

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2
por: Au, Lewis, et al.
Publicado: (2021)

Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male
por: Sutcu, Murat, et al.
Publicado: (2022)

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2
por: Carter, Camryn, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
por: Cáceres, C. Joaquín, et al.
Publicado: (2021)

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
por: Pellini, Raul, et al.
Publicado: (2021)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2
por: Zelini, Paola, et al.
Publicado: (2022)

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
por: Campo, Flaminia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_skcjjsggr2clp9m5uteh5bvanl